Actinium-225 PSMA Therapy Shows Early Promise for Recurrent High-Grade Glioma
A first-in-kind pilot study reports that systemic targeted alpha therapy with actinium-225 labeled PSMA was feasible, well tolerated, and showed ...
A first-in-kind pilot study reports that systemic targeted alpha therapy with actinium-225 labeled PSMA was feasible, well tolerated, and showed ...
In a groundbreaking study poised to redefine therapeutic approaches for prostate cancer, researchers have unveiled a promising combination strategy that ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine